http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-071518-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-38 |
| filingDate | 2009-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa65f7eb8e4373094e9980ae8300c611 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bef4595f804f8b804d9f577abfdcaca2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f55283aa6697f11119b5fcb3e7d5297 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e3084c1d84d54e1e3432a7469c95a57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c6b8fac0a295d4befe6c56a7ea6dfa9 |
| publicationDate | 2010-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-071518-A1 |
| titleOfInvention | ARILPIRAZINONE DERIVATIVES AS STIMULANTS OF THE INSULIN SECRETION METHODS TO OBTAIN THEM AND THEIR USE FOR THE TREATMENT OF DIABETES |
| abstract | Arylpyrazinone derivatives of the formula wherein: (1) R1 is selected from Z; R2 is selected from hydrogen, alkyl, cycloalkyl; R3 is selected from hydrogen, halogen, alkyl, cycloalkyl; A is selected from aryl, heteroaryl, arylalkyl, wherein the alkyl, aryl and heteroaryl groups may be optionally substituted with one or more substituents selected from Y; Z is: alkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, arylthioalkyl, arylalkylthioalkyl, heteroarylalkyl, heteroaryloxyalkyl, heteroarylalkoxyalkyl, heteroarylthioalkyl, heteroarylalkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, heterocycloalkyloxyalkyl, heterocicloalquilalcoxialquilo, heterocicloalquiltioalquilo, heterocicloalquilalquiltioalquilo, arylalkenyl, arylalkynyl, cycloalkyl , cycloalkylalkyl, cycloalkyloxyalkyl, cycloalkylalkoxyalkyl, cycloalkylthioalkyl, cycloalkylalkylthioalkyl, each of these groups may be optionally substituted with one or more substituents selected from Y; And it is: hydroxy, thio, halogen, cyano, trifluoromethoxy, trifluoromethyl, carboxy, carboxymethyl, carboxy ethyl, alkyl, alkoxy, alkylamino, aryl, arylsulfonylalkyl, aryloxy, arylalkoxy, amino, NR5R6, azido, nitro, guanidino, amidino, oxidino , carbamoyl, alkylsulfonyl, alkylsulfinyl, alkylthio, SF5, two Y groups can form a methylenedioxy; R5 and R6 are independently selected from hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, wherein the alkyl, aryl and heteroaryl groups may be optionally substituted with one or more substituents selected from Y, R5 and R6 may constitute together a heterocycle; R2 and R3 may constitute a cycle corresponding to the general formula (2) R1 and A defined as above; n = 3, 4, 5; R4 represents one or more substituents selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, wherein the alkyl, cycloalkyl and aryl groups may be optionally substituted with one or more substituents, selected from hydroxy, halogen, alkyl, alkoxy, trifluoromethoxy, trifluoromethyl , alkylsulfonyl, NR7R8; R7 and R8 are independently selected from hydrogen, alkyl, cycloalkyl; as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs and mixtures thereof and their pharmaceutically acceptable salts. As stimulants of insulin secretion. The preparation and use of these pyrazinone derivatives for the prevention and / or treatment of diabetes and associated pathologies is also provided. |
| priorityDate | 2008-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.